NCT04906109View on ClinicalTrials.gov

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

October 5, 2021

Study Completion Date

October 5, 2021

Conditions

Hepatitis B

Interventions

DRUG

Vemlidy Tab

1T

DRUG

DA-2803 Tab

1T

Trial Locations (1)

05505

Asan Medical Center, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY